Further, a recent discovery shows that CXCR3 expression on Tregs plays a critical role in limiting the endogenous anti-tumor response as well as limiting the clinical efficacy of therapeutic anti-tumor response [67]. The gene discussed is CXCR3; the disease is neoplasm.